Xencor (XNCR) Leerink Global Healthcare Conference 2026 summary

Company overview and strategic priorities

• Focuses on protein and antibody engineering to develop novel monoclonal and bispecific antibodies for oncology and autoimmune diseases.

• Aims to become a fully integrated company by advancing proprietary programs through clinical development to market.

• Key priorities include advancing internal clinical programs, especially XmAb819 (renal cell carcinoma) and XmAb541 (CLDN6+ tumors), and launching new autoimmune disease programs.

• Plans to deliver phase I data for XmAb819 and XmAb541 in 2024, with pivotal trials targeted for 2027.

• XmAb412, a bispecific antibody for autoimmune disease, will have its preclinical data presented at DDW in May.

XmAb819 (ENPP3 x CD3) program highlights

• XmAb819 is a bispecific T cell engager targeting ENPP3 and CD3, designed for high tumor selectivity and reduced toxicity.

• Achieved a 25% objective response rate in heavily pretreated clear cell renal cell carcinoma patients, with durable responses observed.

• Safety profile dominated by early CRS and ENPP3-mediated rash, followed by good tolerability.

• Dose expansion cohorts are ongoing to define the recommended phase III dose, with pivotal studies planned for 2027.

• Expansion into additional tumor types (papillary RCC, NSCLC, colorectal) is underway, leveraging ENPP3 expression profiles.

Commercial and competitive landscape for XmAb819

• Substantial commercial opportunity in RCC, with potential to move into earlier lines as standard therapies compress upfront.

• Market expansion possible in other ENPP3-positive tumors, potentially doubling the addressable population.

• Competitive landscape in clear cell RCC is limited, with XmAb819 seen as a novel and preferred target by clinicians.

• Late-line pivotal study could support blockbuster status, especially in the U.S. and Western Europe.